Publications

  • Treibel TA, Kozor R, Fontana M, Torlasco C, Reant P, Badiani S, Espinoza M, Yap J, Diez J, Hughes AD, Lloyd G, Moon JC. Sex dimorphism in the myocardial response to aortic stenosis. JACC Cardiovasc Imaging 2018;11:962-973. IF (2017): 10.247; Lugar: 7/128 Cardiac and cardiovascular systems; 1er decil.

  • Deckx S, Heggermont W, Carai P, Rienks M,  Dresselaers T, Himmelreich U, van Leeuwen R, Lommen W, van der Velden J, González A, Díez J, Papageorgiou AP, Heymans S. Osteoglycin prevents the development of age-related diastolic dysfunction by reducing cardiac fibrosis and inflammation. Matrix Biology 2018;66:110-124. IF (2017): 8.136; Lugar: 25/292 Biochemistry and molecular biology; 1er decil.

  • González A, Schelbert E, Díez J, Butler J. Myocardial interstitial fibrosis in heart failure: Biological and translational perspective. J Am Coll Cardiol 2018:71:1696-1706. IF (2017): 16.834; Lugar: 3/128 Cardiac and cardiovascular systems; 1er decil.

  • Treibel TA,  López B, González A, Menacho K, Schofield R, Ravassa S, Fontana M, White SK, DiSalvo C, Roberts N, Ashworth M, Díez J, Moon JC. Reappraising myocardial fibrosis in severe aortic stenosis – an invasive and non-invasive study in 133 patients. Eur Heart J 2018;39:699-709. IF (2017): 23.425; Lugar: 1/128 Cardiac and cardiovascular systems; 1er decil.

  • Treibel TA, Kozor R, Schofield R, Benedetti G, Fontana M, Sheikh A, López B, González A, Manisty C, Lloyd G, Kellman P, Díez J, Moon JC. Diffuse myocardial fibrosis - a therapeutic target? Regression at 1-year following aortic valve replacement: The RELIEF-AS study. J Am Coll Cardiol 2018:71:860-871. IF (2017): 16.834; Lugar: 3/128 Cardiac and cardiovascular systems; 1er decil.

  • Verjans R, Peters T, Beaumont J, van Leeuwen R, Bijnen M, Henkens M, Díez J , de Windt LJ, van Bilsen M, Heymans S, González A, Schroen B. The microRNA-221/222 family counteracts myocardial fibrosis in pressure overload-induced heart failure. Hypertension 2018;71:280-288. IF (2017): 6.823; Lugar: 3/65 Peripheral vascular disease; 1er decil.

  • Schelbert EB, Fridman Y, Wong TC, Abu Daya H, Piehler KM, Kadakkal A, Miller CA, Ugander M, Maanja M, Kellman P, Shah DJ, Abebe KZ, Simon MA, Quarta G, Senni M, Butler J, Diez J, Redfield MM, Gheorghiade M. Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: Association with baseline disease severity and subsequent outcome. JAMA Cardiol 2017;2:995-1006. IF (2017): 10.133; Lugar: 8/128 Cardiac and cardiovascular systems; 1er decil.

  • Pérez del Villar C, Savvatis K, López B, Kasner M, Martinez-Legazpi P, Yotti R, González A, Díez J, Fernández-Avilés F, Tschöpe C, Bermejo J. Impact of acute hypertension transients on diastolic function in patients with heart failure with preserved ejection fraction. Cardiovasc Res 2017;113:906-914. IF (2017): 6.290; Lugar: 16/128 Cardiac and cardiovascular systems

  • Micheletti R, Abraham BJ, Sarre A, Ting CC, Alexanian M, Maric D, Mason D, Plaisance I,  Nemir M, Young RA, Schroen B, González A, Ounzain S, Pedrazzini T. The long noncoding RNA WISPER controls cardiac fibrosis and remodeling. Sci Transl Med 2017; 9:eaai9118. IF (2017): 16.710; Lugar: 2/133 Medicine, research and experimental. ; 1er decil.

  • Gyöngyösi M, Winkler J, Ramos I, Do QT, Firat H, McDonald K, González A, Thum T, Díez J, Jaisser F, Pizard A, Zannad F. Myocardial fibrosis: biomedical research from bench to bedside Eur J Heart Fail 2017;19:177-191. IF (2017): 10.683; Lugar: 6/128 Cardiac and cardiovascular systems; 1er decil.

  • Díez J. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. Eur J Heart Fail 2017;19:167-176. IF (2017): 10.683; Lugar: 6/128 Cardiac and cardiovascular systems; 1er decil.

  • López B, Ravassa S, González A, Zubillaga E, Bonavila C, Bergés M, Echegaray K, Beaumont J, Moreno MU, San José G, Larman M, Querejeta R, Díez J. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure. J Am Coll Cardiol 2016;67:251-260. IF (2016): 19.896; Lugar: 2/126 Cardiac and cardiovascular systems; 1er decil.

  • Yang J, Savvatis K, Kang JS, Fan P, Zhong H, Schwartz K, Barry V, Mikels-Vigdal A, Karpinski S, Kornyeyev D, Adamkewicz J, Feng X, Zhou Q, Shang C, Kumar P, Phan D, Kasner M, López B, Diez J, Wright KC, Kovacs RL, Chen PS, Quertermous T, Smith V, Yao L, Tschöpe C, Chang CP. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat Commun 2016;7:13710. IF (2016): 12.124; Lugar: 3/64 Multidisciplinary sciences; 1er decil.

  • Wilcox JE, Fonarow GC, Ardehali H, Bonow RO, Butler J, Sauer AJ, Epstein SE, Khan SS, Kim RJ, Sabbah HN, Díez J, Gheorghiade M. "Targeting the heart" in heart failure: Myocardial recovery in heart failure with reduced ejection fraction. JACC Heart Fail 2015;3:661-669. IF (2015): 7.218; Lugar: 9/124 Cardiac and cardiovascular systems; 1er decil.

  • López B, González A, Ravassa S, Beaumont J, Moreno MU, San José G, Querejeta R,  Díez J. Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. J Am Coll Cardiol 2015;65:2449-2456. IF (2015): 17.759; Lugar: 1/124 Cardiac and cardiovascular systems; 1er decil.

  • Ho CY, Lakdawala NK, Cirino AL, Lipshultz SE, Sparks E, Abbasi SA, Kwong RY, Antman EM, Semsarian C, González A, López B, Diez J, Orav EJ, Colan SD, Seidman CE. Diltiazem treatment for pre-Clinical hypertrophic cardiomyopathy sarcomere mutation carriers: A pilot randomized trial to modify disease expression. JACC Heart Fail 2015;3:180-188. IF (2015): 7.218; Lugar: 9/124 Cardiac and cardiovascular systems; 1er decil.

  • Senni M, Paulus WJ, Gavazzi A, Fraser AG, Díez J, Solomon SD, Smiseth OA, Guazzi M, Lam CSP, Magpregioni AP, Tschöpe C, Hummel SL, Edelmann F, Ambrosio G, Stewart Coats AJ, Filippatos GS, Gheorghiade M, Anker SD, Levy D, Pfeffer MA, Stough WG, Pieske BM. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J 2014;35:2797-2815. IF (2014): 15.203; Lugar: 2/123 Cardiac and cardiovascular systems; 1er decil.

  • López B, González A, Querejeta R, Larman M, Rábago G, Díez J. Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. Hypertension 2014;63:483-489. IF (2014): 6.480; Lugar: 3/60 Peripheral vascular disease; 1er decil.

  • Moreno MU, San José G, Pejenaute Á, Landecho MF, Díez J, Beloqui Ó, Fortuño A, Zalba G. Association of phagocytic NADPH oxidase activity with hypertensive heart disease: a role for cardiotrophin-1? Hypertension 2014;63:468-474. IF (2014): 6.480; Lugar: 3/60 Peripheral vascular disease; 1er decil.

  • Araña M, Gavira JJ, Peña E, González A, Abizanda G, Cilla M, Pérez MM, Albiasu E, Aguado N, Casado M, López B, González S, Soriano M, Moreno C, Merino J, García Verdugo JM, Díez J, Doblare M, Pelacho B, Prosper F. Epicardial delivery of collagen patches with adipose-derived stem cells in rat and minipig models of chronic myocardial infarction. Biomaterials 2014;35:143-151. IF (2014): 8.557; Lugar: 1/33 Material sciences, biomaterials; 1er decil.



"Studies with specific molecules directed against new molecular targets in order to develop new pharmacological interventions that prevent or reverse myocardial damage in heart failure.", Arantxa González, investigadora principal.

Contact

Contact:
Nerea Cano
Avda. Pío XII, 55
31008 Pamplona
España

(+34) 948 194 700 Ext. 3044
ncano@unav.es